FDA approves AstraZeneca's Etcamah for ctDNA-guided breast
The FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) for HR-positive, HER2-negative breast cancer patients with an ESR1 mutation
The FDA has granted accelerated approval to AstraZeneca's camizestrant, to be marketed as Etcamah, for a specific group of breast cancer patients. The oral SERD is approved in combination with a CDK4/6 inhibitor for treating HR-positive, HER2-negative breast cancer upon detection of an ESR1 mutation during initial first-line treatment with an aromatase inhibitor and a CDK4/6 drug.
This decision, announced on a Friday, represents a rare divergence from the FDA's own expert advisory committee, which had overwhelmingly rejected the application. Jefferies analysts described the approval as an important moment for breast cancer care, "not because of the drug itself, but because it validates an entirely new treatment paradigm of ctDNA-guided intervention before radiographic progression."
Serena-6 trial results
The approval is based on findings from the phase 3 Serena-6 trial. The study enrolled HR-positive, HER2-negative breast cancer patients who had not progressed on first-line aromatase inhibitors and CDK4/6 inhibitors, as determined by scans, but who had an emergent ESR1 mutation detected in circulating tumor DNA (ctDNA).
Compared to patients who stayed on their original treatment, those who switched to the Etcamah-CDK4/6 regimen had a 56% lower risk of disease progression or death. Median progression-free survival was 16 months for the novel therapy, versus 9.2 months in the comparator arm. The Etcamah group also showed a 23% risk reduction for tumor progression on next-line treatment or death. Overall survival data, while not mature, showed a trend favoring AstraZeneca's regimen.
| Trial Arm | Median Progression-Free Survival | Risk Reduction (Progression/Death) |
|---|---|---|
| Etcamah + CDK4/6 inhibitor | 16 months | 56% lower risk |
| Continued original treatment | 9.2 months | Comparator |
Regulatory controversy and ctDNA data
Despite the positive trial readout, the FDA's initial review was skeptical. The agency took issue with the Serena-6 trial's design because it did not compare the novel first-line switch approach to the standard practice of waiting until disease progression before switching to an oral SERD. The trial did not allow crossover to Etcamah, and only 14% of control-arm patients received other oral SERDs for subsequent treatment.
During an April advisory committee meeting, experts largely sided with the FDA's concerns. Following overwhelmingly negative reviews, AstraZeneca submitted additional ctDNA analyses at the FDA's request. Data presented at ASCO 2026 showed that by Week 8, total ctDNA levels were reduced by 99% in the Etcamah arm, versus an increase of 64% in the control arm. An exploratory analysis linked reduction of total ctDNA to a 61% improvement in overall survival.
A new treatment paradigm
After a review extension, the FDA changed its position. The accelerated approval obligates AstraZeneca to provide confirmatory evidence in the future. The phase 3 Serena-4 trial, evaluating Etcamah as a first-line treatment regimen, is expected to report topline results this year.
Dave Fredrickson, AstraZeneca's head of oncology hematology business unit, stated on September 4 that the combination "reflects AstraZeneca's leadership in redefining breast cancer care by pioneering a new approach using circulating tumor DNA and is the first and only medicine of its type in the 1st-line setting." By the company's estimate, about 37,000 patients with HR-positive metastatic breast cancer in the U.S. Are treated with a medicine paired with CDK4/6 inhibitors. About 30% may develop ESR1 mutations during first-line treatment before disease progression.
Clinical impact and market context
Kevin Kalinsky, M.D., from Emory University and an investigator for Serena-6, said the approval enables clinicians "to promptly intervene and change therapeutic strategy at an earlier opportunity ahead of disease progression, rather than waiting until the cancer becomes harder to treat."
AstraZeneca has projected Etcamah could reach more than $5 billion in peak annual sales, though the currently approved first-line switch label is only a small part of that ambition. Jefferies analysts suggest the majority of the revenue target likely lies in the early breast cancer setting. The drug faces competition from other oral SERDs like the Menarini Group's Orserdu, Eli Lilly's Inluriyo, and Roche's giredestrant, all targeting the adjuvant setting.
